Sung-Woo Kim

This inventor holds 9 USPTO granted patents, plus 1 CIPO patent and 8 EPO patents. Top assignees: Pharmabcine Inc., Lg Chem, Ltd, Korea Atomic Energy Research Institute. Active years: 2009-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sung-Woo Kim. Retrieved from https://idiyas.com/inventor/sung-woo-kim-cgpq3mps

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 9

% Patents Active = 88.9

CIPO Patents = 1

EPO Patents = 8 (Patent Applications = 5)

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 30(Granted Patents)

Location History:

Seo-gu Daejeon, KR (2014)
Daejeon, KR (2009 - 2020)

Company Filing History:

Korea Atomic Energy Research Institute

patents

Years Active: 2009-2020

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10597457 - EGFRvIII antibody and composition comprising same (2020-03-24),

2. 10106622 - Human antibody specific to c-Met and preparation method thereof (2018-10-23),

3. 9828661 - Nickel-based super heat resistant alloy and method of manufacturing the same (2017-11-28),

4. 9249220 - Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof (2016-02-02),

5. 9249219 - Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof (2016-02-02),

6. 9150650 - Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof (2015-10-06),

7. 8808908 - Battery module of novel structure (2014-08-19),

8. 8067114 - Electrolyte for lithium secondary battery of improved low-temperature property and secondary battery containing the same (2011-11-29),

9. 7476467 - Lithium secondary battery with high power (2009-01-13),

Title: Innovations of Sung-Woo Kim

Introduction

Sung-Woo Kim is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer treatment. With a total of nine patents to his name, Kim's work has the potential to impact therapeutic strategies for various cancers.

Latest Patents

Among his latest patents is the "EGFRvIII antibody and composition comprising same." This patent focuses on an antibody that specifically binds to the epidermal growth factor receptor variant III (EGFRvIII). It includes details about the nucleic acid coding the antibody, a vector containing the nucleic acid, and a method for preparing the antibody. This pharmaceutical composition is aimed at treating cancer or tumors. Another notable patent is the "Human antibody specific to c-Met and preparation method thereof." This invention provides a fully human antibody with high affinity and specificity to c-Met, which is crucial for controlling its activity in vivo.

Career Highlights

Sung-Woo Kim has worked with notable companies in the biotechnology sector, including Pharmabcine Inc. and LG Chem, Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in antibody development.

Collaborations

Some of his coworkers include Jin-San Yoo and Weon-Sup Lee. Their collaborative efforts have likely enhanced the research and development processes in which Kim has been involved.

Conclusion

Sung-Woo Kim's innovative work in antibody development showcases his commitment to advancing cancer treatment. His patents reflect a deep understanding of biotechnology and a dedication to improving therapeutic options for patients.

Profile summary based on public USPTO records.